Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression.

Authors:
Omar D Perez
Omar D Perez
Stanford University School of Medicine
United States
Christopher R Logg
Christopher R Logg
University of California
United States
Kei Hiraoka
Kei Hiraoka
Keiyukai Sapporo Hospital
Japan
Ryan Burnett
Ryan Burnett
The Scripps Research Institute
United States
Akihito Inagaki
Akihito Inagaki
Gifu University School of Medicine
Japan

Mol Ther 2012 Sep 1;20(9):1689-98. Epub 2012 May 1.

Tocagen Inc, San Diego, California 92109, USA.

Retroviral replicating vectors (RRVs) are a nonlytic alternative to oncolytic replicating viruses as anticancer agents, being selective both for dividing cells and for cells that have defects in innate immunity and interferon responsiveness. Tumor cells fit both these descriptions. Previous publications have described a prototype based on an amphotropic murine leukemia virus (MLV), encoding yeast cytosine deaminase (CD) that converts the prodrug 5-fluorocytosine (5-FC) to the potent anticancer drug, 5-fluorouracil (5-FU) in an infected tumor. We report here the selection of one lead clinical candidate based on a general design goal to optimize the genetic stability of the virus and the CD activity produced by the delivered transgene. Vectors were tested for titer, genetic stability, CD protein and enzyme activity, ability to confer susceptibility to 5-FC, and preliminary in vivo antitumor activity and stability. One vector, Toca 511, (aka T5.0002) encoding an optimized CD, shows a threefold increased specific activity in infected cells over infection with the prototype RRV and shows markedly higher genetic stability. Animal testing demonstrated that Toca 511 replicates stably in human tumor xenografts and, after 5-FC administration, causes complete regression of such xenografts. Toca 511 (vocimagene amiretrorepvec) has been taken forward to preclinical and clinical trials.

Download full-text PDF

Source
http://dx.doi.org/10.1038/mt.2012.83DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437576PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
September 2012
396 Reads

Publication Analysis

Top Keywords

toca 511
16
genetic stability
12
retroviral replicating
8
stability
5
higher genetic
4
tumor report
4
stability animal
4
infected tumor
4
5-fu infected
4
5-fluorouracil 5-fu
4
report selection
4
drug 5-fluorouracil
4
markedly higher
4
based general
4
general design
4
design goal
4
rrv markedly
4
candidate based
4
selection lead
4
lead clinical
4

Similar Publications